Forge expands footprint with new office and lab space in Torrey Mesa, San Diego
-"What it Means to be Handcrafted in San Diego" Open House Event to Commemorate New Space- San Diego, California, March 12, 2018 – Forge ...
Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference
-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH ...
Forge therapeutics announces participation in upcoming scientific and industry events
San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and ...
-
Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas GalleryForge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas
Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas
- BLACKSMITH Platform Initially Focused on the Development of Novel Classes of Antibiotics - - Expansion Highlights Significance of US-UK Biotech Partnerships – ...
Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum
Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum San Diego, California, October 11, 2017 – Forge Therapeutics, Inc., ...
Forge Therapeutics to present at World Anti-Microbial Resistance Congress 2017
San Diego, California, September 12, 2017 – Forge Therapeutics, Inc., (Forge) announced today that the company will present a talk entitled, “Forging new ...
-
Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 2017 GalleryForge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 2017
Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 2017
San Diego, California, September 7, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced new preclinical data ...
Forge Therapeutics and Evotec to present preclinical data on novel antibiotic program at 2017 ASM/ESCMID Conference
San Diego, California, August 29, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced today that the ...
Forge Therapeutics forms scientific advisory board with world renowned antibiotic and drug development experts
San Diego, California, July 26, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, ...
Forge Therapeutics to present at 2017 Bio International Convention
SAN DIEGO, California, June 12, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, ...